Every Form 4 that Avalo Therapeutics, Inc. (AVTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AVTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVTX filings page.
Avalo Therapeutics director Mitchell Chan exercised restricted stock units that vested into common shares. On March 28, 2026, 3,166 restricted stock units converted into 3,166 shares of common stock at a conversion price of $0.00 per share.
Following the transaction, Chan directly owned 6,333 shares of Avalo Therapeutics common stock. The restricted stock units convert into common stock on a one-for-one basis and are part of a 9,500-unit grant that vests in three equal annual installments starting March 28, 2025.
Avalo Therapeutics director Jonathan Goldman exercised restricted stock units into common shares. On March 28, 2026, 3,166 restricted stock units converted into 3,166 shares of Avalo Therapeutics common stock at an exercise price of $0.00 per share. This reflects a derivative exercise, not an open-market purchase or sale.
According to prior grant terms, Goldman received 9,500 restricted stock units on August 13, 2024, vesting in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, contingent on continued service.
Avalo Therapeutics, Inc. Chief Medical Officer Mittie Doyle exercised stock options and sold shares in a linked set of transactions. On March 16, 2026, she exercised options to acquire 19,500 shares of common stock at $12.65 per share and 5,992 shares at $8.04 per share.
The same day, she sold 25,492 shares of common stock in open-market transactions at an average price of about $16.1465 per share, in multiple trades between $16.00 and $16.34. Following these transactions, she directly holds 3,622 common shares.
Avalo Therapeutics, Inc. reported that Chief Legal Officer Paul Varki received a grant of stock options covering 80,000 shares on February 26, 2026. The options have an exercise price of $0.00 per share, reflecting a compensatory award rather than a market purchase.
According to the vesting terms, 25% of the option grant will vest on February 26, 2027, with the remaining 75% vesting in equal monthly installments over the following three years. Vesting is conditioned on Varki's continued service with the company on each applicable vesting date.
Avalo Therapeutics reported that Chief Strategy Officer Jennifer Riley received a grant of stock options giving her the right to buy 95,000 shares of common stock. The award was reported at a price of $0.00 per share, reflecting a compensatory option grant rather than an open-market trade.
According to the disclosure, the option vests 25% on February 26, 2027, with the remaining shares vesting in equal monthly installments over the following three years, as long as she continues in service on each vesting date. This filing shows an increase in her derivative equity holdings through a grant/award acquisition, not a sale of existing shares.
Avalo Therapeutics, Inc. disclosed that Chief Medical Officer Mittie Doyle received a grant of stock options for 105,000 shares on February 26, 2026. The option has an exercise price reported as $0.0000 per share. Twenty‑five percent vests on February 26, 2027, with the remaining options vesting in equal monthly installments over the following three years, conditioned on continued service.
Boyd Taylor reported acquisition or exercise transactions in this Form 4 filing.
Avalo Therapeutics, Inc. reported that its Chief Business Officer, Boyd Taylor, received a grant of stock options covering 95,000 shares. The options were awarded as a derivative security and are held directly.
The award vests 25% on February 26, 2027, with the remaining options vesting in equal monthly installments over the following three years, subject to Boyd Taylor’s continued service on each vesting date.
Sullivan Christopher Ryan reported acquisition or exercise transactions in this Form 4 filing.
Avalo Therapeutics reported that its Chief Financial Officer, Christopher Ryan Sullivan, received a grant of stock options representing 105,000 shares of common stock. These options were awarded on February 26, 2026 as an equity-based compensation grant.
The stock option vests 25% on February 26, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, conditioned on his continued service. After this grant, Sullivan held 105,000 stock options directly.
NEIL GARRY ARTHUR reported acquisition or exercise transactions in this Form 4 filing.
Avalo Therapeutics, Inc. reported that Chief Executive Officer Neil Garry Arthur received a grant of stock options covering 286,000 shares on February 26, 2026. The option vests 25% on February 26, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, subject to his continued service.
Avalo Therapeutics, Inc. reported an insider Form 4 transaction by its Chief Medical Officer. On December 10, 2025, the officer disposed of 1,013 shares of Avalo Therapeutics common stock at $4.1 per share. After this transaction, the officer beneficially owns 3,622 shares, which include shares acquired pursuant to Avalo Therapeutics' Employee Stock Purchase Plan as part of this reporting transaction.
Avalo Therapeutics’ chief strategy officer reported a small change in personal share holdings. On 12/10/2025, the officer disposed of 637 shares of Avalo Therapeutics common stock at a price of $4.1 per share, according to an SEC insider ownership report.
After this transaction, the officer directly beneficially owns 2,655 shares of Avalo Therapeutics. These 2,655 shares are described as having been acquired under the company’s Employee Stock Purchase Plan as part of the reported activity, indicating ongoing participation in the company’s equity programs.
Avalo Therapeutics, Inc. reported an equity transaction by its Chief Legal Officer on December 10, 2025. The officer reported a transaction in Avalo common stock coded “F” involving 1,016 shares at a price of $4.10 per share. After this transaction, the officer beneficially owns 3,634 shares of Avalo common stock. A note explains that these 3,634 shares were acquired under Avalo’s Employee Stock Purchase Plan as part of the reported transaction.
Avalo Therapeutics, Inc. chief financial officer Christopher Sullivan reported a change in his ownership of Avalo common stock. On 12/10/2025, 155 shares of common stock were disposed of at $4.1 per share, leaving him with beneficial ownership of 17,338 shares.
The beneficially owned amount includes 417 additional shares acquired pursuant to Avalo Therapeutics, Inc.'s Employee Stock Purchase Plan as a part of this reporting transaction. The report is a Form 4 filed by one reporting person in his capacity as an officer (chief financial officer).
Avalo Therapeutics, Inc. (AVTX) reported insider activity by one of its directors involving common stock and stock options on November 14, 2025. The director exercised a stock option to acquire 8,200 shares of common stock at an exercise price of $9.88 per share and then sold those 8,200 shares at a weighted average price of $14.3474 per share. On the same date, the director also sold an additional 3,167 shares of common stock at $14.30 per share, for total reported sales of 11,367 shares. Following these transactions, the director reported owning 0 shares of common stock directly and 16,400 stock options with an exercise price of $9.88 per share, expiring on August 13, 2034, which vest in three equal annual installments on March 28, 2025, 2026 and 2027.